3-(2-amino-1-cyclohexylethyl)-4H-1,2,4-oxadiazol-5-one;hydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(2-amino-1-cyclohexylethyl)-4H-1,2,4-oxadiazol-5-one;hydrochloride
• 化学式: C10H18ClN3O2
• 分子量: 247.72
• InChiKey: BSGXJWYTYNFMHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.41
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  76.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Method of treating cartilage damage
  申请人：——

  公开号：US20020072533A1

  公开（公告）日：2002-06-13

  The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  该发明涉及通过给予类似GABA的类似物，例如Formula1的化合物及其药学上可接受的盐，来预防或治疗软骨损伤的方法，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Method of treating tinnitus
  申请人：——

  公开号：US20030176504A1

  公开（公告）日：2003-09-18

  The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  这项发明涉及通过给予α2δ配体治疗耳鸣的方法，例如，给予一种符合化学式1的化合物及其药用盐，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
  申请人：Roark Howard William

  公开号：US20050004177A1

  公开（公告）日：2005-01-06

  This invention relates to a combination of an allosteric inhibitor of matrix metalloproteinase-13, or a pharmaceutically acceptable salt thereof, and a ligand to an alpha-2-delta receptor, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the combination, and a method of using the combination to treat a disease or disorder in a mammal suffering therefrom, wherein the disease or disorder is responsive to treatment in one aspect by an allosteric inhibitor of MMP-13 and in the same or a different aspect by a ligand to an alpha-2-delta receptor.

  这项发明涉及一种基质金属蛋白酶-13的变构抑制剂，或其药用盐，以及α-2-δ受体的配体，或其药用盐的组合，包括该组合的药物组合物，以及使用该组合来治疗哺乳动物患有的疾病或紊乱的方法，其中该疾病或紊乱在一方面通过MMP-13的变构抑制剂治疗，在另一方面或不同方面通过α-2-δ受体的配体治疗。
• Method of treating attention deficit hyperactivity disorder
  申请人：——

  公开号：US20040006073A1

  公开（公告）日：2004-01-08

  This invention relates to a method of treating ADHD by administering an alpha2delta ligand such as, for example, gabapentin or pregabalin, or a pharmaceutically acceptable salt thereof.

  这项发明涉及通过给予α2δ配体（例如加巴喷丁或普雷加巴林或其药用盐）来治疗注意力缺陷多动障碍的方法。
• Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
  申请人：——

  公开号：US20030199567A1

  公开（公告）日：2003-10-23

  The invention relates to a combination, comprising a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, and an Alpha-2-delta ligand, or a pharmaceutically acceptable salt thereof, and valdecoxib. Examples of selective inhibitors of COX-2 include valdecoxib, rofecoxib, and celecoxib. Examples of Alpha-2-delta ligands include gabapentin, pregabalin, (3S,4S)-( 1 -Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, and 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride. The combinations are useful for treating certain diseases including cartilage damage, inflammation, pain, and arthritis.

  本发明涉及一种组合物，包括COX-2的选择性抑制剂或其药学上可接受的盐，以及Alpha-2-delta配体或其药学上可接受的盐和瓦尔德考昔。 COX-2的选择性抑制剂的例子包括瓦尔德考昔，罗非昔布和塞来昔布。 Alpha-2-delta配体的例子包括加巴喷丁，普拉巴林，（3S，4S）-（1-氨甲基-3,4-二甲基-环戊基）-乙酸和3-（1-氨甲基-环己基甲基）-4H-[1,2,4]噁二唑-5-酮盐酸盐。该组合物可用于治疗某些疾病，包括软骨损伤，炎症，疼痛和关节炎。